Patents by Inventor Min Jeong BAEK

Min Jeong BAEK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10039841
    Abstract: The present invention relates to a replication retrovirus vector system comprising thymidine kinase (HSV-TK) gene and cytosine deaminase (CD) gene which make gene transfer to cancer cell tissue for the efficient treatment of cancer. Particularly, the HSV-TK/CD combined self-replicating retrovirus vector system of the present invention characteristically contains both HSV-TK and CD genes; has no worries about losing a therapeutic gene because recombination does not occur in this system during virus infection; and has an excellent stability, and also is able to induce cancer cell death by using the prodrug GCV or 5-FC and can apply a therapeutic gene or a prodrug thereof selectively to such cancer that shows resistance against cancer treatment using either TK or CD, so that this system of the invention can be advantageously used as a pharmaceutical composition for the treatment of cancer.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 7, 2018
    Assignee: THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventors: Yeon Soo Kim, Moonkyung Kang, Min Jeong Baek
  • Publication number: 20180147299
    Abstract: The present invention relates to a replication retrovirus vector system comprising thymidine kinase (HSV-TK) gene and cytosine deaminase (CD) gene which make gene transfer to cancer cell tissue for the efficient treatment of cancer. Particularly, the HSV-TK/CD combined self-replicating retrovirus vector system of the present invention characteristically contains both HSV-TK and CD genes; has no worries about losing a therapeutic gene because recombination does not occur in this system during virus infection; and has an excellent stability, and also is able to induce cancer cell death by using the prodrug GCV or 5-FC and can apply a therapeutic gene or a prodrug thereof selectively to such cancer that shows resistance against cancer treatment using either TK or CD, so that this system of the invention can be advantageously used as a pharmaceutical composition for the treatment of cancer.
    Type: Application
    Filed: November 30, 2016
    Publication date: May 31, 2018
    Applicant: The Industry & Academic Cooperation in Chungnam National University (IAC)
    Inventors: Yeon Soo KIM, Moonkyung KANG, Min Jeong BAEK